Imexpharm targets VND2,981 billion in total revenue in 2025
Imexpharm aims for VND2,981 billion in total revenue and VND493.5 billion in profit before tax in 2025, focusing on high-tech products, R&D, and market expansion.
Topic: Pharmacist Tran Thi Dao
Imexpharm achieves VND594 billion in Q1 net revenue
Imexpharm kicked off Q1 2025 with impressive results, reporting net revenue of VND594 billion and profit before tax of VND95 billion in Q1 2025, up 21 per cent and 23 per cent year-on-year (YoY), respectively.
Imexpharm's green strategy to build a sustainable future
The Imexpharm Pharmaceutical Joint Stock Company is committed to significantly investing in sustainable development as a strategic path to drive its future expansion into the global market.
Imexpharm recognized at Top 50 Corporate Sustainability Awards
The Imexpharm Pharmaceutical Joint Stock Company has been listed in the Top 50 Corporate Sustainability Awards 2023 held by the Nhip Cau Dau Tu - The BusinessReview magazine.